5-bromo-2-{[4-(4-diethylamino-but-2-ynyloxy)-benzenesulfonyl]-methyl-amino}-3-methyl-benzoic acid | 287109-11-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 5-bromo-2-{[4-(4-diethylamino-but-2-ynyloxy)-benzenesulfonyl]-methyl-amino}-3-methyl-benzoic acid
• 英文别名: 5-Bromo-2-[[4-[4-(diethylamino)but-2-ynoxy]phenyl]sulfonyl-methylamino]-3-methylbenzoic acid
• CAS: 287109-11-9
• 化学式: C₂₃H₂₇BrN₂O₅S
• 分子量: 523.448
• InChiKey: WHDHXHZPSODCQE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  32
• 可旋转键数：
  9
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  95.5
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  5-bromo-2-{[4-(4-diethylamino-but-2-ynyloxy)-benzenesulfonyl]-methyl-amino}-3-methyl-benzoic acid 在 草酰氯 、 羟胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 5-Bromo-2-{[4-(4-diethylamino-but-2-ynyloxy)-benzenesulfonyl]-methyl-amino}-N-hydroxy-3-methyl-benzamide
  参考文献：
  名称：

  Anthranilate sulfonamide hydroxamate TACE inhibitors. Part 2: SAR of the acetylenic P1′ group

  摘要：

  The SAR of a series of potent sulfonamide hydroxamate TACE inhibitors bearing novel acetylenic P1' groups was explored. In particular, compound 4t bearing a butynylox P1' moiety has excellent in vitro potency against isolated TACE enzyme and in cells, good selectivity over MMP-1 and oral activity in an in vitro model of TNF-alpha production. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)00136-1
• 作为产物：
  描述：

  5-Bromo-2-{[4-(4-diethylamino-but-2-ynyloxy)-benzenesulfonyl]-methyl-amino}-3-methyl-benzoic acid methyl ester 在 sodium hydroxide 作用下， 生成 5-bromo-2-{[4-(4-diethylamino-but-2-ynyloxy)-benzenesulfonyl]-methyl-amino}-3-methyl-benzoic acid
  参考文献：
  名称：

  Anthranilate sulfonamide hydroxamate TACE inhibitors. Part 2: SAR of the acetylenic P1′ group

  摘要：

  The SAR of a series of potent sulfonamide hydroxamate TACE inhibitors bearing novel acetylenic P1' groups was explored. In particular, compound 4t bearing a butynylox P1' moiety has excellent in vitro potency against isolated TACE enzyme and in cells, good selectivity over MMP-1 and oral activity in an in vitro model of TNF-alpha production. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)00136-1

文献信息

• Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
  申请人：American Cyanamid Company

  公开号：US20010056088A1

  公开（公告）日：2001-12-27

  Hydroxamic acids having the formula 1 are useful in treating disease conditions mediated by TNF-&agr;, such as rheumatoid arthritis, osteoarthritis, sepsis, AIDS, ulcerative colitis, multiple sclerosis, Crohn's disease and degenerative cartilage loss.

  具有公式1的羟肟酸在治疗由TNF-α介导的疾病状况方面是有用的，例如类风湿性关节炎、骨关节炎、败血症、艾滋病、溃疡性结肠炎、多发性硬化症、克罗恩病和退行性软骨丢失。
• ACETYLENIC ARYL SULFONAMIDE AND PHOSPHINIC ACID AMIDE HYDROXAMIC ACID TACE INHIBITORS
  申请人：Wyeth Holdings Corporation

  公开号：EP1144369B1

  公开（公告）日：2004-07-21
• US6277885B1
  申请人：——

  公开号：US6277885B1

  公开（公告）日：2001-08-21
• US6762178B2
  申请人：——

  公开号：US6762178B2

  公开（公告）日：2004-07-13
• [EN] ACETYLENIC ARYL SULFONAMIDE AND PHOSPHINIC ACID AMIDE HYDROXAMIC ACID TACE INHIBITORS<br/>[FR] INHIBITEURS D'ENZYME TACE D'ACIDE HYDROXAMIQUE D'ARYLSULFONAMIDE ACETYLENIQUE ET D'AMIDE ACIDE PHOSPHINIQUE
  申请人：AMERICAN CYANAMID CO

  公开号：WO2000044710A2

  公开（公告）日：2000-08-03

  Hydroxamic acids having formula (B) wherein the variables are as defined herein, are useful in treating disease conditions mediated by TNF-α such as rheumatoid arthritis, osteoarthritis, sepsis, AIDS, ulcerative colitis, multiple sclerosis, Crohn's disease and degenerative cartilage loss.